Generalised and partial lipodystrophies are rare, complex and clinically heterogeneous disorders, characterised by varying degrees of adipose tissue loss, leading to leptin deficiency. Low levels of leptin result in ectopic fat deposition, insulin resistance, diabetes and hypertriglyceridaemia. In many cases, these effects can result in severe, life-threatening abnormalities including hepatic steatosis, pancreatitis, cirrhotic steatohepatitis and early-onset atherosclerosis.

The information in this activity is intended for healthcare professionals involved in the diagnosis and treatment of patients with lipodystrophy.

This touchSYMPOSIUM HIGHLIGHTS was recorded live during the 21st European Congress of Endocrinology (ECE) in May 2019.

EXPERT PERSPECTIVES

DR GIOVANNI CECCARINI

  • Obesity and Lipodistrophy Center
  • University Hospital of Pisa
  • Pisa, Italy

Disclosures

Consulting for Aegerion

Overview

Giovanni Ceccarini outlines the characteristics and pathogenesis of lipodystrophy and explains the role of leptin in the disease process, as well as describing the symptoms that should raise suspicion of lipodystrophy in a patient.

DR MICHAEL STUMVOLL

  • IFB Adiposity Diseases
  • University of Leipzig
  • Leipzig, Germany

Disclosures

Research project for AstraZeneca; speaker fees for Novartis, Lilly and Aegerion; advisory boards for Novo Nordisk Foundation and Novartis

Overview

Michael Stumvoll discusses the challenges, goals, and optimal timing of the treatment of generalised and partial lipodystrophy with metreleptin.

This video is intended for health care professionals.

Information for patients and carers can be found here.
Product information on metreleptin is available here.

Adverse reactions should be reported to Aegerion by email: Medinfo.emea@aegerion.com or by telephoning the free phone number: 00800 234 37466

PROFESSOR FERRUCCIO SANTINI

  • Obesity and Lipodistrophy Center
  • University Hospital of Pisa
  • Pisa, Italy

Overview

Ferruccio Santini discusses the role of specialist centres in managing lipodystrophy patients, including diagnostic tests performed, and the need for resources and a multidisciplinary team for patient management.

DR REBECCA SANDERS

  • Lipodystrophy patient
  • Co-founder and Chair of Lipodystrophy UK
  • Oxford, UK

Overview

Rebecca Sanders describes the challenges faced by patients with lipodystrophy, highlights the need for increased awareness and education to improve patient care, and provides information on patient support organisations.

DR CAMILLE VATIER

  • Endocrinology, Diabetology and Reproductive Endocrinology Department
  • Hôpital Saint-Antoine AP-HP
  • Paris, France

Faculty Disclosures

Has received personal fees for consultancy, travel or accommodation from Aegerion Pharmaceuticals, Lilly, Novo Nordisk, Sanofi, Servier, and Vitalaire

Overview

Read a summary of Camille Vatier’s Meet the Expert session that took place at the 21st European Congress of Endocrinology (ECE) in May 2019.

The report can be downloaded from the ‘Meet the Expert report’ download section below.

EXPERT PERSPECTIVES

DR GIOVANNI CECCARINI

  • Obesity and Lipodistrophy Center
  • University Hospital of Pisa
  • Pisa, Italy

Disclosures

Consulting for Aegerion

Overview

Giovanni Ceccarini outlines the characteristics and pathogenesis of lipodystrophy and explains the role of leptin in the disease process, as well as describing the symptoms that should raise suspicion of lipodystrophy in a patient.

DR MICHAEL STUMVOLL

This video is intended for health care professionals.

Information for patients and carers can be found here.
Product information on metreleptin is available here.

Adverse reactions should be reported to Aegerion by email: Medinfo.emea@aegerion.com or by telephoning the free phone number: 00800 234 37466

  • IFB Adiposity Diseases
  • University of Leipzig
  • Leipzig, Germany

Disclosures

Research project for AstraZeneca; speaker fees for Novartis, Lilly and Aegerion; advisory boards for Novo Nordisk Foundation and Novartis

Overview

Michael Stumvoll discusses the challenges, goals, and optimal timing of the treatment of generalised and partial lipodystrophy with metreleptin.

PROFESSOR FERRUCCIO SANTINI

  • Obesity and Lipodistrophy Center
  • University Hospital of Pisa
  • Pisa, Italy

Overview

Ferruccio Santini discusses the role of specialist centres in managing lipodystrophy patients, including diagnostic tests performed, and the need for resources and a multidisciplinary team for patient management.

DR REBECCA SANDERS

  • Lipodystrophy patient
  • Co-founder and Chair of Lipodystrophy UK
  • Oxford, UK

Overview

Rebecca Sanders describes the challenges faced by patients with lipodystrophy, highlights the need for increased awareness and education to improve patient care, and provides information on patient support organisations.

DR CAMILLE VATIER

  • Endocrinology, Diabetology and Reproductive Endocrinology Department
  • Hôpital Saint-Antoine AP-HP
  • Paris, France

Faculty Disclosures

Has received personal fees for consultancy, travel or accommodation from Aegerion Pharmaceuticals, Lilly, Novo Nordisk, Sanofi, Servier, and Vitalaire

Overview

Read a summary of Camille Vatier’s Meet the Expert session that took place at the 21st European Congress of Endocrinology (ECE) in May 2019.

The report can be downloaded from the ‘Meet the Expert report’ download section below.

SYMPOSIUM PRESENTATIONS

Lipodystrophy: A shared journey for patients and care teams

Watch an internationally renowned faculty discuss the lipodystrophy journey through diagnosis, treatment options and patient experiences. Prof. Ferruccio Santini, Dr Giovanni Ceccarini, Dr Michael Stumvoll and Dr Rebecca Sanders outline the need for management and support by specialised teams to ensure accurate diagnosis, access to treatment and dietary advice, with the aim of reducing early mortality and morbidity in patients with lipodystrophy.

This video is intended for health care professionals.

Information for patients and carers can be found here.
Product information on metreleptin is available here.

Adverse reactions should be reported to Aegerion by email: Medinfo.emea@aegerion.com or by telephoning the free phone number: 00800 234 37466

Please provide feedback for this touchSYMPOSIUM HIGHLIGHTS on the following (scale 1-5, 1 strongly disagree; 5 strongly agree):